易明医药: 股票交易异常波动公告

Group 1 - The company, Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd., experienced abnormal stock trading fluctuations on June 5 and June 6, 2025, as per the relevant regulations [1] - The board of directors confirmed that there are no undisclosed significant matters affecting the company's stock price, apart from the disclosed share transfer agreement with Beijing Fuhai, which involves the acquisition of 43,855,883 shares from the controlling shareholder Gao Fan [1][2] - The company has disclosed the necessary documents regarding the change of control, including a brief and detailed report on equity changes, and has confirmed that there are no other undisclosed matters that could impact the stock price [2] Group 2 - The company will continue to comply with legal and regulatory requirements for information disclosure and will ensure timely updates regarding any significant changes [2] - The completion of the equity change is subject to compliance confirmation from the Shenzhen Stock Exchange and other necessary approvals, indicating potential uncertainties in the implementation of the transaction [2]